THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to ...
Amgen Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha® (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke Published Mar ...
Repatha (evolocumab) is an injectable medicine that helps lower levels of low-density lipoprotein cholesterol (LDL), often called “bad” cholesterol. Approved in 2015, Repatha can now be used in adults ...
The FDA has expanded approval of Amgen’s PCSK9 inhibitor Repatha (evolocumab), permitting use in adults at increased risk of major adverse cardiovascular events due to uncontrolled LDL cholesterol, ...
The FDA expanded Repatha's label to include adults at increased risk for MACE due to uncontrolled LDL-C, broadening access beyond those with diagnosed CVD. Repatha is now approved as a standalone ...
March 27 (Reuters) - Amgen Inc's (AMGN.O), opens new tab battle with Sanofi (SASY.PA), opens new tab and Regeneron (REGN.O), opens new tab at the U.S. Supreme Court over its cholesterol drug Repatha ...
Matthew Herper covers medical innovation — both its promise and its perils. Amgen said Thursday that its cholesterol-lowering shot, Repatha, prevented a composite of heart disease death, heart attack, ...
As copycats eat into Amgen’s older products, the big biotech is looking to its newer launches to stem the tide. But some of them are not getting it done. JPMorgan analyst Cory Kasimov name-dropped ...
SANTA MONICA, Calif., October 06, 2025--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® (evolocumab), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback